Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhu SL, Gao Q, Liu Y, Cheng KP. Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis. World J Gastrointest Surg 2026; 18(11): 122614 [DOI: 10.4240/wjgs.122614]
World J Gastrointest Surg. Nov 27, 2026; 18(11): 122614 Published online Nov 27, 2026. doi: 10.4240/wjgs.122614
Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis
Shan-Ling Zhu, Qian Gao, Yang Liu, Kun-Peng Cheng
Shan-Ling Zhu, Qian Gao, Yang Liu, Kun-Peng Cheng, Department of Gastroenterology Medicine, Huangshi Fifth Hospital, Huangshi 435005, Hubei Province, China
Author contributions: Zhu SL performed the study; Zhu SL, Gao Q, and Liu Y analyzed the data; Cheng KP designed the research and wrote the manuscript. All authors have read and approve the final manuscript.
AI contribution statement: No AI tools were used in the preparation of this manuscript.
Institutional review board statement: Given the retrospective design and data anonymization, approval from the ethics review committee is waived.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Received: June 10, 2026 Revised: July 16, 2026 Accepted: August 26, 2026 Published online: November 27, 2026 Processing time: 154 Days and 19 Hours
Abstract
BACKGROUND
The management of gastroparesis (GP) following radical gastrectomy (RGE) for gastric cancer (GC) remains challenging, and treatment optimization is needed because current therapeutic approaches have limited efficacy.
AIM
To investigate the clinical efficacy and safety of omeprazole (OME) combined with cisapride (CIS) in the treatment of GP after RGE in patients with GC.
METHODS
A total of 198 patients with post-RGE GP were retrospectively enrolled from September 2020 to September 2025. Patients were grouped according to treatment regimen: 92 patients receiving OME constituted the control group, and 106 patients receiving OME plus CIS comprised the research group. Outcomes included clinical efficacy, symptom improvement assessed using the GP Cardinal Symptom Index, gastrointestinal function recovery (time to bowel sound recovery, nasogastric tube removal, and resumption of a normal diet), gastrointestinal hormone levels (gastrin and motilin), and safety (diarrhea, abdominal pain, headache/dizziness, palpitations, and nausea). Factors influencing treatment efficacy were subsequently evaluated.
RESULTS
The research group showed a significantly higher total effective rate than the control group. Following treatment, GP Cardinal Symptom Index scores across all domains were lower, the time to bowel sound recovery, nasogastric tube removal, and normal diet resumption was shorter, and gastrin and motilin levels were higher in patients receiving the combination therapy. The incidence of total adverse reactions was comparable between the two groups. Tumor-node-metastasis staging, baseline motilin level, and treatment regimen were independent factors affecting treatment efficacy.
CONCLUSION
OME combined with CIS is effective for treating GP after RGE for GC without increasing the overall incidence of adverse reactions. Additionally, stage IIB-III disease, baseline motilin < 309 mg/L, and treatment with OME alone are associated with an increased risk of treatment inefficacy.
Core Tip: This retrospective study evaluated the clinical efficacy and safety of omeprazole (OME) combined with cisapride in patients with gastroparesis following radical gastrectomy for gastric cancer. The combination regimen was more effective than OME alone without increasing the overall incidence of adverse reactions. It also demonstrated clinical advantages in promoting symptom relief, accelerating gastrointestinal function recovery, and actively regulating gastrointestinal hormones. Patients with stage IIB-III disease, baseline motilin < 309 mg/L, and treatment with OME alone were at increased risk of treatment inefficacy.
